FREMONT, Calif., April 11 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems (Nasdaq: CIPH) today announced that the company and
collaborators from M.D. Anderson Cancer Center at the University of Texas
will present data supporting Ciphergen's ovarian cancer diagnostics program
at the 2007 Annual Meeting of the American Association for Cancer Research
(AACR) to be held April 14-18, 2007, at the Los Angeles Convention Center,
Los Angeles, CA.
To follow are the presentation details:
Title: Proteomics discovery of urinary biomarkers for early
stage ovarian cancer
Abstract Number: 594
Poster Session: Sunday, April 15, 2007, 8:00 AM - 12:00 PM
About Ciphergen
Ciphergen Biosystems, Inc. is dedicated to the discovery, development
and commercialization of novel high-value diagnostic tests that help
physicians diagnose, treat and improve outcomes for patients. Ciphergen,
along with its prestigious scientific collaborators, has ongoing diagnostic
programs in oncology, cardiology and women's health with an initial focus
in ovarian cancer. Based in Fremont, California, more information about
Ciphergen can be found on the Web at http://www.ciphergen.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below and
others that can be found in Ciphergen's Form 10-K for the year ended Dec.
31, 2006, and in Ciphergen's periodic reports on Form 10-Q and Form 8-K.
Ciphergen is providing this information as of the date of this news release
and does not undertake any obligation to update any forward-looking
statements contained in this document as a result of new information,
future events or otherwise.
SOURCE Ciphergen Biosystems, Inc.
 back to top
Related links:
http://www.ciphergen.com/
CONTACT:
Sue Carruthers, Investor Relations of
Ciphergen Biosystems, Inc., +1-510-505-2297; or media, Lori
Murray of WeissComm Partners, +1-415-946-1070, for Ciphergen
Biosystems, Inc.
|
